[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Hoshi A, Tokunaga M, Usui Y, Yamashita H, Sasaki H, Kobayashi Y, Shima M, Miyakita H, Terachi T: [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan]. Hinyokika Kiyo; 2005 Jan;51(1):41-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan].
  • Transitional cell carcinoma (TCC) frequently metastasizes to lymph nodes, liver, lungs and bone.
  • We report two cases of bladder tumor which metastasized to the ileum.
  • Case 1: A 87-year-old man had a history of bladder tumor (TCC, grade 3, pT2bN0M0) and has transurethral resection of bladder tumor (TUR-BT) three times.
  • As computed tomography (CT) showed abdominal free air, our diagnosis was perforation of gastrointestinal tract.
  • Cystoscopy showed a non-papillary broad based tumor in the right wall of the bladder.
  • CT showed a bladder tumor invaded into the prostate (pT4aN1M0), we performed total cyctectomy and ileal conduit after neo-adjuvant chemotherapy.
  • During the operation, we found the tumor (2 cm in diameter) in the small intestine which was metastasized of bladder tumor.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732341.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


2. Yokoyama S, Tsutahara K, Fukuhara S, Mori N, Hara T, Yamaguchi S, Adachi S: [Small cell carcinoma of the urinary bladder: a case report]. Hinyokika Kiyo; 2005 Jun;51(6):403-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the urinary bladder: a case report].
  • We report a case of primary small cell carcinoma of the urinary bladder.
  • Cystoscopy showed a papillary tumor.
  • We operated transurethral resection of the bladder tumor (TUR-Bt).
  • Histopathological finding was transitional cell carcinoma (TCC), grade3, pT1 containing pTis.
  • About six months later, tumor recurred to the bladder.
  • Pathologic diagnosis was TCC in part and most was small cell carcinoma.
  • Pelvic magnetic resonance imaging revealed a huge mass lesion with extravesical extension in the urinary bladder, and computed tomography scan showed external iliac lympho node metastasis.
  • It was diagnosed as a rapid advance of small cell carcinoma.
  • We performed pelvic radiotherapy, and chemotherapy using carboplatin (CBDCA) and etoposide (VP-16).
  • However 14 months after it had left hospital, computed tomography showed paraaortic lympho node metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050481.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Tamura K, Inoue K, Fukata S, Kamada M, Shuin T: [Small cell carcinoma of the urinary bladder with synchronous esophageal cancer and incidental lung cancer: a case report]. Hinyokika Kiyo; 2001 Apr;47(4):273-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the urinary bladder with synchronous esophageal cancer and incidental lung cancer: a case report].
  • We present a case of triple primary cancers occurring synchronously in the urinary bladder, esophagus, and incidentally in the lung.
  • A 65-year-old man with a chief complaint of gross hematuria was admitted to our hospital.
  • Cystoscopy, computed tomography (CT) and magnetic resonance imaging (MRI) revealed a non-papillary broad-based bladder tumor.
  • Histological diagnosis was transitional cell carcinoma of the urinary bladder and he underwent one course of neoadjuvant chemotherapy (M-VAC) with the preoperative diagnosis of T3bN0M0.
  • After one course of chemotherapy, chest CT, lymph node biopsy and esophagoscopy revealed squamous cell carcinoma of the esophagus.
  • He first underwent radiochemotherapy (total 70 Gy, CDDP 5 mg x 41, 5-FU 250 mg x 24) for esophageal cancer and achieved complete remission.
  • Then, he underwent radiotherapy for a total of 60 Gy for bladder cancer.
  • The autopsy proved that he died from multiple metastases of small cell carcinoma of the urinary bladder and incidentally squamous cell carcinoma of the lung was identified.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Esophageal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / pathology


Advertisement
4. Shigehara K, Kobori Y, Amano T, Takemae K: [Bilateral tuberculous epididymitis after intravesical Bacillus Calmette-Guerin therapy]. Hinyokika Kiyo; 2005 Dec;51(12):839-42
Hazardous Substances Data Bank. ISONIAZID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral tuberculous epididymitis after intravesical Bacillus Calmette-Guerin therapy].
  • A 72-year-old man received transuretheral resection of bladder transitional cell carcinoma in November 2000.
  • Although he had no recurrence for about 4 years, cystoscopy revealed small papillary tumors in the bladder in September 2004.
  • Histological diagnosis was bilateral tuberculous epididymitis.
  • [MeSH-minor] Administration, Intravesical. Aged. Carcinoma, Transitional Cell / therapy. Combined Modality Therapy. Drug Therapy, Combination. Humans. Isoniazid / administration & dosage. Male. Orchiectomy. Rifampin / administration & dosage. Urinary Bladder Neoplasms / therapy

  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440736.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / BCG Vaccine; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


5. Hoshi K, Kaneto H, Imai Y, Ikeda Y, Naganuma H: [Inverted papilloma of the urinary bladder: three case reports]. Hinyokika Kiyo; 2002 Oct;48(10):629-31
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inverted papilloma of the urinary bladder: three case reports].
  • We report three cases of inverted papilloma of the urinary bladder. Case 1.
  • Cystoscopy revealed a smooth-surfaced tumor on a stalk at the bladder neck.
  • Histological diagnosis was inverted papilloma.
  • As a safe guard, intravesical chemotherapy (Adriamycin) was performed, since pathological findings revealed a small region with mild atypical cells in the removed tumor.
  • A 63-year-old male was admitted to our hospital because of a bladder tumor incidentally found by abdominal ultrasonography.
  • Histological diagnosis was inverted papilloma.
  • A smooth-surfaced tumor found at the bladder neck was removed transurethrally.
  • Histological diagnosis was inverted papilloma.
  • Three months later, cystoscopy revealed two sessile papillary tumors on the left lateral wall of the urinary bladder.
  • Pathological diagnosis was transitional cell carcinoma (G2, pTa).
  • Although the inverted papilloma is a benign tumor, there is a possibility of recurrence or development of transitional cell carcinoma.
  • [MeSH-major] Papilloma, Inverted / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491619.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Segawa N, Kotake Y, Hamada S, Takahara K, Azuma H, Katsuoka Y, Tsuji M: [Bladder cancer with skin metastasis: a case report]. Hinyokika Kiyo; 2006 Sep;52(9):711-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder cancer with skin metastasis: a case report].
  • Bladder carcinoma with skin metastasis is extremely rare.
  • We herein report a case of a bladder tumor with skin metastasis.
  • Cystoscopy revealed a trigone papillary tumor.
  • Transurethral resection of bladder tumor (TURBT) was performed and the pathological diagnosis was transitional cell carcinoma (TCC), pT1, G3.
  • Thereafter, he received several courses of TURBT, intravesical chemotherapy (pirarubicin, bacillus Calmette-Guerin and mitomycin C) and intra-arterial chemotherapy because of recurrence.
  • Histological examination revealed muscle-invasive bladder cancer with a staging of T3bNOM0.
  • This indicated metastatic spread from the primary bladder TCC.
  • He received only supportive treatment during this period due to renal dysfunction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / secondary. Skin Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Administration, Intravesical. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Infusions, Intra-Arterial. Male. Methotrexate / administration & dosage. Mitomycin / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040057.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Ide H, Nakajima Y, Horinaga M, Shinojima T, Ozu C, Hatakeyama N, Kiguchi H: [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):813-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report].
  • Cystoscopy showed broad-based papillary tumors on the left bladder wall.
  • TUR-BT was performed and pathological diagnosis was grade 3 transitional cell carcinoma of pT1a.
  • Although no intravesical tumor recurrence had been observed, a solid palpable mass was noted in the lower abdomen nine months after TUR-BT, and computed tomography suggested a large ovarian tumor.
  • Frozen sections of the tumor were diagnosed as transitional cell carcinoma metastases of the bladder cancer, and the final pathological report was the same.
  • Although receiving 4 courses of M-VAC systemic chemotherapy after the operation, she died 14 months later.
  • Autopsy disclosed intraperitoneal cancer dissemination and metastases without any intravesical nor left perivesical tumor recurrence, and it was suggested that the bladder tumor metastases occurred not by direct invasion but by either lymphatic or vascular mechanism in this case.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Neoplastic Cells, Circulating / pathology. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624492.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM: An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol; 2008 Oct;180(4):1297-300; discussion 1300
MedlinePlus Health Information. consumer health - Statins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
  • PURPOSE: Bacillus Calmette-Guerin is an effective immunotherapy for carcinoma in situ of the bladder and it reduces recurrence from resected papillary transitional cell carcinoma of the bladder.
  • Many patients receiving bacillus Calmette-Guerin therapy are concurrently taking statin agents, which have known immunomodulatory properties and may alter the performance of bacillus Calmette-Guerin.
  • Some data have suggested that patients taking a statin while on bacillus Calmette-Guerin therapy experience reduced clinical efficacy.
  • Time to recurrence and progression to surgery were compared between those taking and those not taking a statin by Kaplan-Meier methods and multivariable Cox regression controlling for stage and grade.
  • RESULTS: There were 245 (26%) patients taking a statin before bacillus Calmette-Guerin therapy and 707 not on statin therapy (74%).
  • Median time to recurrence was similar between those who did and those who did not use a statin.
  • On multivariable analysis statin use was not significantly associated with recurrence (hazard ratio 1.04; 95% CI 0.81, 1.34; p = 0.7) or progression to surgery (hazard ratio 0.77; 95% CI 0.52, 1.13; p = 0.17) after bacillus Calmette-Guerin therapy.
  • CONCLUSIONS: This retrospective study in a large cohort of patients showed no statistically significant association between statin use and recurrence or progression to open surgery in patients treated with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
  • Based on these data patients should not be discouraged from taking statins while undergoing bacillus Calmette-Guerin treatment.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Cohort Studies. Disease Progression. Drug Therapy, Combination. Evaluation Studies as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Reference Values. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707737.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


9. Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, Jung SJ, Choi YJ, Ayala AG: Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol; 2008 May;32(5):752-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
  • In this report, we summarized the clinicopathologic features of 9 cases of plasmacytoid transitional cell carcinoma (TCC) of the urinary bladder, a rare variant of TCC.
  • All 9 patients were men with a mean of age 64.3 years (range, 46 to 81 y).
  • Cystoscopic findings revealed a dominant solid mass with surrounding multiple papillary lesions in 6 cases and multiple masslike lesions in 3 other cases.
  • The initial diagnosis of plasmacytoid TCC was made on transurethral resection in 8 cases and cystoscopic biopsy in 1.
  • Four patients were treated by radical cystectomy with chemotherapy, 2 by radical cystectomy alone, 1 each by chemotherapy or intravesical bacillus Calmette-Guerin infusion alone, and 1 did not receive any further therapy.
  • Eight of 9 cases were associated with high-grade TCC, and transitional cell carcinoma in situ was present in 4 cases.
  • Interestingly, plasmacytoid transitional cell carcinoma in situ was noted in 1 case.
  • The mean follow-up in 8 patients was 24.5 months (range, 5 to 47 mo); the other patient was lost to follow-up.
  • Morphologic recognition and distinction from other plasmacytoid malignant neoplasms is critical for its clinical management and immunohistochemical studies may be required for differential diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Plasma Cells / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Combined Modality Therapy. Cystoscopy. Cytoplasm / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379419.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Katusin D, Poka Z, Mlinac-Lucijanić M, Kriz M, Klarić-Vucinić S, Ilijanić J: [Carcinoma in situ in the urinary bladder]. Lijec Vjesn; 2000 Jul-Aug;122(7-8):177-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ in the urinary bladder].
  • [Transliterated title] Karcinom in situ mokraćnog mjehura.
  • In this paper we have presented seven patients with carcinoma in situ of the urinary bladder, a rare intraepithelial form of transitional cell carcinoma of the urinary bladder, described first in 1952.
  • In all patients malignant cells were detected in urine sediment, and the diagnosis was proven histopathologicaly by random biopsies of the urinary bladder.
  • In five patients carcinoma in situ was associated with papillary bladder tumor, while two patients had primary carcinoma in situ.
  • Three patients had reduced bladder capacity.
  • In all patients a complete response was achieved after local immunotherapy or local chemotherapy.
  • After a follow-up lasting from 23 to 61 months in one patient a recurrent carcinoma in situ was diagnosed, while six patients show no signs of recurrent disease.
  • [MeSH-major] Carcinoma in Situ. Carcinoma, Transitional Cell. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048460.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] CROATIA
  •  go-up   go-down


11. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer; 2001 Jul-Aug;25(4):219-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of superficial bladder cancer.
  • Bladder cancer is the fourth leading cause of cancer in American men, accounting for more than 12,000 deaths annually.
  • Currently, cigarette smoking is by far the most common cause of bladder cancer, although occupational exposure to arylamines has been implicated in the past.
  • Initial radiologic evaluation usually includes the excretory urography (intravenous pyelography), although further evaluation of the renal parenchyma with ultrasound or computed tomography scanning has been advocated by some.
  • These radiologic studies are unable to provide adequate bladder imaging, and thus cystoscopy is required for the diagnosis of bladder cancer.
  • Most bladder cancers present as "superficial" disease, confined to the bladder mucosa or submucosal layer, without muscle invasion.
  • Superficial tumors consist of papillary tumors that are mucosally confined (Ta), papillary or sessile tumors extending into the lamina propria (T1), and carcinoma in situ, which occurs as "flat" mucosal dysplasia, which can be focal, diffuse, or associated with a papillary or sessile tumor.
  • It is important to identify those tumors at risk for recurrence or progression so that adjuvant intravesical therapies can be instituted.
  • Most are given intravesically on a weekly basis, although many studies suggest that a single instillation immediately after transurethral resection may be as good as a longer course of therapy.
  • Although all of these drugs have toxicity, they usually are well tolerated.
  • Intravesical bacille Calmette-Guérin (BCG) is an immunotherapeutic agent that when given intravesically is very effective in the treatment of superficial transitional cell carcinoma.
  • Compared with controls, BCG has a 43% advantage in preventing tumor recurrence, a significantly better rate than the 16% to 21% advantage of intravesical chemotherapy.
  • In addition, BCG is particularly effective in the treatment of carcinoma in situ, eradicating it in more than 80% of cases.
  • In contrast to intravesical chemotherapy, BCG has also been shown to decrease the risk of tumor progression.
  • Unfortunately, adverse effects associated with this prolonged therapy may limit its widespread applicability.
  • In those patients at high risk in whom BCG therapy fails, intravesical interferon-alpha with or without BCG may be beneficial in some.
  • Photodynamic therapy has also been used but is limited by its toxicity.
  • In patients who progress or do not respond to intravesical therapies, cystectomy should be considered.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Immunotherapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] ABO Blood-Group System. Administration, Intravesical. Adult. Aged. Diagnosis, Differential. Female. Hematuria / etiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Photochemotherapy. Risk Factors. Surgical Procedures, Operative / methods. Urethra / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11514784.001).
  • [ISSN] 0147-0272
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 179
  •  go-up   go-down


12. Babjuk M, Dvorácek J: [Diagnosis and therapy of superficial tumors of the urinary bladder]. Cas Lek Cesk; 2002 Nov 22;141(23):723-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of superficial tumors of the urinary bladder].
  • [Transliterated title] Diagnostika a terapie povrchových nádorů mocového mĕchýre.
  • Among patients with bladder carcinoma, 70-80% present with superficial bladder tumors.
  • This group is composed of papillary tumors Ta, T1 and of flat nonpapillary high-grade carcinoma in situ (Tis).
  • Typical features of superficial tumors are their multifocal origin and high recurrence-rate after initial therapy.
  • The first and most important step in diagnosis and treatment of the bladder cancer is urethrocystoscopy under general or spinal anesthesia with resection of papillary lesions and biopsy of suspicious areas followed by pathologic examination of the surgical specimen.
  • The aims of intravesical therapy are treatment of Tis and prevention of recurrence and progression after TUR.
  • The most often used agents for intravesical chemotherapy are mitomycin C and adriamycin.
  • This treatment modality prolongs tumor-free interval and reduces early recurrence-rate in about 14% of patients, but cannot reduce late recurrence-rate and progression-rate.
  • BCG intravestical immunotherapy is with 73-87% response rate the most effective treatment modality in Tis.
  • It is also more effective than chemotherapy in prevention of recurrence, but is connected with more frequent side effects.
  • Radical cystectomy is considered in patients who do not respond to local therapy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650028.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 50
  •  go-up   go-down


13. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L: Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol; 2000 Aug;164(2):349-51
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin.
  • PURPOSE: We determined the sensitivity and specificity of detecting flat bladder carcinoma in situ through fluorescent detection after intravesical hypericin instillations.
  • RESULTS: All visible papillary tumors showed red fluorescence.
  • Analysis of 281 biopsies from flat bladder wall indicated 93% sensitivity and 98.5% specificity for detecting carcinoma in situ.
  • Visible lesions resulting from radiotherapy, chemotherapy or immunotherapy did not show any fluorescent signs and, therefore, did not induce false-positive readings.
  • CONCLUSIONS: We report a simple yet comprehensive endoscopic method for early detection of bladder cancer, including carcinoma in situ.
  • Hypericin induced fluorescence has a high sensitivity and specificity for detection of bladder transitional cell carcinoma, papillary and flat carcinoma in situ.
  • When carcinoma in situ is suspected, this technique is highly recommended.
  • [MeSH-major] Carcinoma in Situ / pathology. Fluorescence. Perylene / analogs & derivatives. Photosensitizing Agents / administration & dosage. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Administration, Intravesical. Carcinoma, Transitional Cell / pathology. Humans. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10893582.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


14. Izawa JI, Grossman HB: Localized bladder cancer. Curr Treat Options Oncol; 2000 Dec;1(5):423-32
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized bladder cancer.
  • Transitional cell carcinoma (TCC) of the bladder makes up 90% of bladder cancers.
  • The approach to the management of localized TCC includes accurate clinical and histologic diagnosis and staging with pathologic material obtained through endoscopy.
  • Once the diagnosis of superficial TCC has been established, histologically based prognostic factors guide which therapy or combination of therapies is indicated in the management of individual patients.
  • Surgery alone (transurethral resection) is appropriate initial therapy for noninvasive papillary TCC.
  • For lamina propria invasive tumors and carcinoma in situ, intravesical immunotherapy with bacille Calmette-Guérin (BCG) is often the first line of treatment to decrease tumor recurrence and to possibly decrease progression and improve survival.
  • Intravesical chemotherapy and interferon are alternative therapies that can also decrease recurrence rates.
  • For BCG-refractory TCC, durable response rates with alternative intravesical therapies are low.
  • For superficial TCC that is refractory to endoscopic procedures and intravesical agents or for disease progression, radical cystectomy with neobladder formation or other forms of urinary diversion is the treatment of choice.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cystectomy. Diet. Endoscopy. Humans. Immunotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):137-46, [10696252.001]
  • [Cites] J Urol. 1999 Apr;161(4):1133-5; discussion 1135-6 [10081854.001]
  • [Cites] Urology. 2000 Feb;55(2):161-8 [10688071.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3603-10 [9721868.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1404-8 [7751885.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):103-13, ix [10696249.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):934-41 [7853578.001]
  • [Cites] J Urol. 1996 Sep;156(3):962-6 [8709374.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):15-24, vii-viii [10696241.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):1-13, vii [10696240.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1298-301 [9552029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] J Clin Oncol. 1994 Jan;12 (1):7-13 [8270987.001]
  • [Cites] BJU Int. 2000 Mar;85(5):599-610 [10735935.001]
  • [Cites] Br J Urol. 1998 May;81(5):692-8 [9634043.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):455-65 [1636230.001]
  • [Cites] J Urol. 1998 Jun;159(6):1793-801 [9598463.001]
  • [Cites] J Urol. 1994 Jan;151(1):21-6 [8254816.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):171-8, xi [10696256.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1390-7 [10228189.001]
  • [Cites] J Urol. 1999 Apr;161(4):1120-3 [10081851.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1159-64 [8320745.001]
  • [Cites] J Urol. 1986 May;135(5):920-2 [3959241.001]
  • [Cites] Urology. 1997 Oct;50(4):529-35 [9338727.001]
  • [Cites] CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84 [9742894.001]
  • [Cites] Semin Surg Oncol. 1997 Sep-Oct;13(5):291-8 [9259084.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):125-35, x [10696251.001]
  • [Cites] Eur Urol. 1995;28(4):284-90 [8575494.001]
  • [Cites] J Urol. 1999 Aug;162(2):445-50; discussion 450-1 [10411054.001]
  • [Cites] Cancer. 1999 Jun 25;87(3):118-28 [10385442.001]
  • (PMID = 12057150.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  • [Number-of-references] 34
  •  go-up   go-down


15. Watts KE, Hansel DE: Emerging concepts in micropapillary urothelial carcinoma. Adv Anat Pathol; 2010 May;17(3):182-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging concepts in micropapillary urothelial carcinoma.
  • Micropapillary urothelial carcinoma is a relatively uncommon variant of urothelial carcinoma, but its recognition carries important prognostic and treatment implications.
  • On account of this association, micropapillary features in urothelial carcinoma should be reported regardless of whether the pattern is focal or dominant.
  • The overall prognosis for micropapillary urothelial carcinoma is poor and recent studies suggest that early treatment with cystectomy could improve outcome, as these tumors are unlikely to respond to chemotherapy when used as a secondary treatment modality.
  • This review discusses the histologic features required for diagnosis and the clinical significance of rendering a diagnosis of micropapillary urothelial carcinoma.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Transitional Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418672.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


16. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Urinary bladder biopsies showed a carcinoma with micropapillary features diagnosed as micropapillary transitional cell carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The urinary bladder and endometrial biopsies both contained carcinomas with micropapillary features.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • The tumor cells from the breast, endometrium, and urinary bladder were positive for cytokeratin (CK) 7 and estrogen receptor and negative for CK20.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • Immunohistochemical stains are useful in distinguishing these lesions in that thyroid transcription factor-1 positivity suggests a lung primary, CK7 and estrogen receptor suggest a breast primary, and both CK7 and CK20 positivity suggest a urinary bladder primary.
  • It is important to exclude metastatic carcinomas with micropapillary features before making a definite diagnosis of a primary tumor.
  • This article discusses the differential diagnosis of carcinomas with micropapillary features in different organs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


17. Masuda A, Minakmi S, Usui Y, Arihara K, Nagata Y, Kawamura N: Advanced bladder cancer in a young female: a case report. Tokai J Exp Clin Med; 2001 Jul;26(2):39-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced bladder cancer in a young female: a case report.
  • We present a rare case of advanced bladder cancer in a young female.
  • A clinical examination revealed a papillary, broad-based bladder tumor with a clinical stage of T3, N3, M0.
  • Preoperatively, 3 courses of neoadjuvant chemotherapy with methotrexate, adriamycin, and cisplatin were performed, and proved to be effective.
  • Radical cystectomy was done and the histopathologically it was diagnosis as Grade 2 transitional cell carcinoma, which did not show any p53 gene mutation.
  • Bladder carcinoma in patients under 30 years of age tends to have a early stage and a low grade.
  • However, the above described 27-year-old female patient demonstrated the advanced stage bladder tumor.
  • Therefore, it should be kept in mind to accurately evaluate young patients with transitional cell carcinoma of the bladder and not to rule out the possibility of advanced disease even though a patient is young.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Doxorubicin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11806441.001).
  • [ISSN] 0385-0005
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Dalbagni G: The management of superficial bladder cancer. Nat Clin Pract Urol; 2007 May;4(5):254-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of superficial bladder cancer.
  • From review of the currently available trial evidence, several clinical recommendations for bladder tumor management become apparent.
  • Transurethral resection should be done, but this procedure is prone to both overestimating and underestimating staging.
  • Data support the immediate postoperative instillation of a chemotherapeutic agent for patients with solitary, low-grade papillary tumors, whereas patients with multiple lesions might benefit from a more intensive adjuvant regimen.
  • Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette-Guérin has demonstrated significant benefit for tumor prophylaxis when no obvious residual disease is present.
  • Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion.
  • In this Review I present an overview of the management of nonmuscle invasive bladder cancer.
  • The most common intravesical chemotherapeutic agents are described as well as the impact of chemotherapy on the recurrence and progression of tumors.
  • The effect of intravesical immunotherapy in bladder cancer is explored as well as the role of early cystectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Transitional Cell / therapy. Cystectomy / methods. Immunotherapy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. BCG Vaccine / administration & dosage. Cystoscopy / methods. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483810.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 62
  •  go-up   go-down


19. Josephson DY, Pasin E, Stein JP: Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther; 2006 Dec;6(12):1723-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
  • Superficial 'nonmuscle-invasive' bladder tumors represent a heterogeneous group of cancers, which include those that are papillary in nature and limited to the mucosa (Ta), high grade, flat and confined to the epithelium (Tis) and those that invade the submucosa or lamina propria (T1).
  • The natural history of these bladder cancers is that of disease recurrence and progression to higher grade and stage.
  • Furthermore, recurrence and progression rates of superficial bladder cancer vary according to several tumor characteristics.
  • The goal in the treatment of superficial bladder cancer is twofold: reducing tumor recurrence and the subsequent need for additional therapies, such as cystoscopy, transurethral resections, intravesical therapy and the morbidity associated with these treatments; and preventing tumor progression and the subsequent need for more aggressive therapy, such as radical cystectomy.
  • The administration of intravesical chemotherapy and immunotherapy has become an important component in accomplishing these goals.
  • This update is the first part of two articles reviewing important contemporary concepts in the etiology, classification and natural history of superficial bladder cancer, while part II of the series will review and highlight important aspects in management of superficial bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Carcinogens, Environmental / adverse effects. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / etiology. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Chromosome Aberrations. Diagnosis, Differential. Disease Progression. Hematuria / etiology. Humans. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Occupational Diseases / chemically induced. Papilloma / diagnosis. Papilloma / pathology. Risk Factors. Smoking / adverse effects. Urinary Tract Infections / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181486.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 124
  •  go-up   go-down


20. Wang WM, Ye M, Chen JH, Zhang L, Kong L, Zhu YJ: [Comparison of endoscopic irsection and vaporization for superficial bladder cancer]. Zhonghua Zhong Liu Za Zhi; 2003 May;25(3):292-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of endoscopic irsection and vaporization for superficial bladder cancer].
  • OBJECTIVE: To evaluate the method and clinical value of endoscopic surgery by comparing endoscopic resection and vaporization for superficial bladder tumor.
  • METHODS: 396 patients with superficial bladder papillary transitional cell carcinoma were treated by endoscopic therapy.
  • 180 patients (Group A) were treated by transurethral resection of bladder tumor (TURBT) and 216 (Group B) by transurethral vaporization of bladder tumor (TVBT).
  • Periodic postoperative intra-vascular instillation of chemotherapy was given to both groups.
  • Operating time, amount of bleeding during operation, complications and recurrence rate were compared.
  • The operating time, recurrence rate in group B were similar to those in group A.
  • CONCLUSION: Transurethral vaporization of bladder cancer, with simplicity in maneuver, less bleeding and fewer complications, rates better in effectiveness and clinical value than resection.
  • [MeSH-major] Cystoscopy / methods. Electrosurgery / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Stavropoulos NE, Kim A, Nseyo UU, Tsimaris I, Chung TD, Miller TA, Redlak M, Nseyo UO, Skalkos D: Hypericum perforatum L. extract - novel photosensitizer against human bladder cancer cells. J Photochem Photobiol B; 2006 Jul 3;84(1):64-9
Hazardous Substances Data Bank. METHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericum perforatum L. extract - novel photosensitizer against human bladder cancer cells.
  • The polar methanolic fraction (PMF) of the Hypericum perforatum L. extract has recently been developed and tested as a novel, natural photosensitizer for use in the photodynamic therapy (PDT), and photodynamic diagnosis (PDD).
  • In the present study, the efficacy of PMF as a phototoxic agent against urinary bladder carcinoma has been studied using the T24 (high grade metastatic cancer), and RT4 (primary low grade papillary transitional cell carcinoma) human bladder cancer cells.
  • Following cell culture incubation, PMF was excited using 630 nm laser light.
  • The photosensitizer exhibited significant photocytotoxicity in both cell lines at a concentration of 60microg/ml, with 4-8 J/cm(2) light dose, resulting in cell destruction from 80% to 86%.
  • At the concentration of 20microg/ml PMF was not active in either cell line.
  • These results were compared with the results obtained in the same cell lines, under the same conditions with a clinically approved photosensitizer, Photofrin.
  • In the T24 cell Photofrin exhibited slightly less photocytotocixity, compared with PMF, resulting in 77% cell death with 8J/cm(2) light dose.
  • However, against the RT4 cells Photofrin resulted in minimal cell death (9%) with even 8J/cm(2) light dose.
  • Finally, the type of cell death induced by PMF photoactivation was studied using flow cytometry and DNA laddering.
  • Cell death by PMF photodynamic action in these two bladder cell lines is caused predominently by apoptosis.
  • [MeSH-major] Apoptosis / drug effects. DNA Fragmentation. Hypericum / chemistry. Methanol / chemistry. Photosensitizing Agents / pharmacology. Phytotherapy. Plant Extracts / pharmacology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Radiation. Humans. Lasers. Light. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540336.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Plant Extracts; Y4S76JWI15 / Methanol
  •  go-up   go-down


22. Granel B, Serratrice J, Morange PE, Disdier P, Weiller PJ: Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin. Clin Exp Rheumatol; 2004 Jul-Aug;22(4):481-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infections and/or immune-mediated reactions may occur after intravesical instillation of bacillus Calmette-Guérin for the treatment of bladder carcinoma.
  • We report herein a cryoglobulinemia vasculitis occurring after intravesical BCG instillation for a superficial papillary transitional cell bladder carcinoma.
  • The patient was treated with heparin and prostacyclins with a good outcome.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Administration, Intravesical. Aged. Aged, 80 and over. Humans. Male. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301249.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


23. Cordon-Cardo C, Cote RJ, Sauter G: Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl; 2000;(205):82-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular genetic changes reported in bladder tumors can be classified as primary and secondary aberrations.
  • There are characteristic primary abnormalities involved in th production of low-grade/well-differentiated neoplasms, which destabilize cellular proliferation but have little effect on cellula "social" interactions or differentiation, as well as the rate of cell death or apoptosis.
  • Other molecular events lead to high-grad neoplasms which disrupt growth control, including the cell cycle and apoptosis, and which have a major impact on biological behavior.
  • A primary target leading to low-grade papillary superficial bladder tumors resides on chromosome 9, while p53 gene alterations are commonly seen in flat carcinoma in situ.
  • Novel approaches utilizing tissue microdissection techniques an molecular genetic assays are needed to shed further light on this subject.
  • Multiple molecular abnormalities are identified in most human cancers studied, including bladder neoplasms.
  • These particular molecular aberrations may be especially important to evaluate for their use in the management of bladder cancer because of their commonality in progressive forms of the disease.
  • Thus, clinical trials are underway to explore their use in specific situations, particularly in the surgical management of locally advanced disease, and to determine whether adjuvant chemotherapy in such patients may be of benefit.
  • The use of molecular alterations in the management of non-invasive bladder neoplasms remains to be firmly established.
  • Our knowledge of molecular alterations important in bladder cancer progression is far from complete, and further study is necessary to further elucidate cruci pathways involved in progression and therapeutic response.
  • Nevertheless, molecular alterations involving chromosome 9q and the INK4A locus in papillary superficial tumors vs changes in chromosomes 14q and 8q, p53 and RB in flat carcinoma in situ lesions may indicate a molecular basis for early events that lead to varying pathways in urothelial tumorigenesis.
  • Clinical advances in bladder cancer will be facilitated by novel animal models paralleling the human disease.
  • Molecular diagnostics, particularly specific antigen expression, fluorescence in situ hybridization and microsatellite analyses, have show great promise as screening and follow-up methodologies, and may supplement urine cytology in the diagnosis and characterization of new and recurrent disease.
  • In addition, the use of high-throughput genomic/proteomic assays, linked to comprehensive databases, and coupled with robust bioinformatics will be key elements in elucidating the components of regulatory and signaling pathways involved in bladder tumorigenesis and cancer progression.
  • [MeSH-major] Carcinoma in Situ / genetics. Carcinoma, Transitional Cell / genetics. Genetic Markers / genetics. Precancerous Conditions / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Humans. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11144907.001).
  • [ISSN] 0300-8886
  • [Journal-full-title] Scandinavian journal of urology and nephrology. Supplementum
  • [ISO-abbreviation] Scand J Urol Nephrol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 111
  •  go-up   go-down


24. Tanaka K, Hara I, Takenaka A, Kawabata G, Fujisawa M: Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology; 2008 Apr;71(4):728-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included 162 radical prostatectomies, 67 radical nephrectomies, 20 partial nephrectomies, 45 nephroureterectomies, 5 retroperitoneal lymph node dissections of testicular cancers after chemotherapy, 3 radical cystectomies, and 2 other procedures.
  • No patients without a histologic diagnosis of cancer were included in this study.
  • RESULTS: Of the 304 patients with cancer, 4 (1.3%) developed a local recurrence, including after retroperitoneal lymph node dissection in 2 patients, radical nephrectomy in 1, and radical cystectomy in 1.
  • The histologic type of both testicular cancers was mixed germ cell tumor, with one occurring in a renal hilar lymph node and the other in a paraaortic lymph node and kidney.
  • The histologic type of the renal cell carcinoma was papillary renal cell carcinoma with sarcomatoid features (Stage pT3aN1), and it occurred in a retrocaval lymph node.
  • The histologic type of the bladder cancer was transitional cell carcinoma, Grade 3, Stage pT4aN0, and it presented as peritoneal carcinomatosis 11 months postoperatively.
  • However, two recurrences were found in 5 patients who had undergone retroperitoneal lymph node dissection for testicular cancer after chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279936.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement